Bruker (BRKR) Misses Q2 Estimates, Is It Still Only 1% Undervalued?
Bruker stock reacts to Q2 earnings miss and cautious guidance
Bruker (BRKR) drew attention after Q2 revenues of US$838.5 million grew 5.2% year on year but came in 1.9% below analyst estimates, with slightly softer full year revenue guidance and a 7.3% share price drop.
For context, Bruker shares have a 1-day share price return of 5.34% and a 7-day share price return of 3.44% after the earnings reaction. However, the 30-day share price return is down 8.23%, hinting that recent momentum has faded. This comes as the year-to-date share price return of 22.68% contrasts with a very large 1-year total shareholder return of 102.09% and weaker total shareholder returns over three and five years.
Compare Bruker’s post earnings reset with hand picked research tools peers that our screener flags as potentially better positioned on fundamentals using 54 high quality undervalued stocks.
After that sharp reset, Bruker now sits between a strong 1 year run and weaker multi year returns. Investors may consider whether it makes more sense to step in after this pullback or wait for an even cheaper entry as the valuation picture becomes clearer.
Most Popular Bruker Narrative: 1.2% Undervalued
Bruker last closed at $59.02 compared with a widely followed narrative fair value of $59.75, which suggests only a small valuation gap and places more weight on the story behind the numbers.
The analysts have a consensus price target of $59.75 for Bruker based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $70.0, and the most bearish reporting a price target of just $40.0.
Want to see what is sitting underneath that tight valuation band for Bruker? The story focuses on rising margins, faster earnings and a richer future earnings multiple. Curious which assumptions really carry this fair value and which could prove most sensitive?
Result: Fair Value of $59.75 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Bruker’s story could still be knocked off course if research funding in the US and China weakens further, or if tariff and FX pressures intensify.
Find out about the key risks to this Bruker narrative.
Next Steps
With Bruker presenting both concerns and reasons for optimism, it makes sense to move quickly and review the full picture for yourself using 3 key rewards and 1 important warning sign.
Looking for more Bruker investment ideas?
If Bruker has your attention, do not stop here. The market is full of other opportunities that could suit your goals just as well.
- Target resilient cash generators by scanning a 75 resilient stocks with low risk scores that filters for companies with steadier risk profiles.
- Spot potential bargains early by reviewing a 20 high quality undiscovered gems built around strong fundamentals that the market may not fully appreciate yet.
- Hunt for robust financial footing using a list of solid balance sheet and fundamentals (52 results) that focuses on companies with healthier balance sheets and underlying strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com